Related Experiment Video
Updated: Jul 10, 2026

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
Current prophylactic and therapeutic uses of a recombinant Lactococcus lactis strain secreting biologically active
Luis G Bermúdez-Humarán1, Naima G Cortes-Perez, Sandrine Ah-Leung
1Unité d'Ecologie et de Physiologie du Système Digestif, INRA, Jouy-en-Josas, France. luis.bermudez@jouy.inra.fr
Abstract:
The noninvasive and food-grade Gram-positive bacterium Lactococcus lactis is well adapted to deliver medical proteins to the mucosal immune system. In the last decade, the potential of live recombinant lactococci to deliver such proteins to the mucosal immune system has been investigated. This approach offers several advantages over the traditional systemic injection, such as easy administration and the ability to elicit both systemic and mucosal immune responses. This paper reviews the current research and advances made with recombinant L. lactis as live vector for the in situ delivery of biologically active interleukin-12, a potent pleiotropic cytokine with adjuvant properties when co-delivered with vaccinal antigens, at mucosal surfaces. Three well-illustrated examples demonstrate the high potential of interleukin-12-secreting lactococci strains for future prophylactic and therapeutic uses.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Inhibitors of Viral Protein Synthesis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

